Tribune News Service
New Delhi, September 16
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Dr. Reddy’s Laboratories Ltd (Dr. Reddy’s), a worldwide pharmaceutical firm headquartered out of India, on Wednesday agreed to cooperate on medical trials and distribution of Sputnik V vaccine in India.
Upon regulatory approval in India, RDIF shall provide to Dr. Reddy’s 100 million doses of the vaccine. The Sputnik V vaccine, which is predicated on well-studied human adenoviral vector platform with confirmed security, is present process medical trials for the coronavirus pandemic.
Deliveries might probably start in late 2020 topic to completion of profitable trials and registration of the vaccine by regulatory authorities in India.
The settlement between RDIF and Dr Reddy’s displays the rising consciousness of nations and organisations to have a diversified anti-COVID vaccine portfolio to guard their populations, Dr Reddy’s stated.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, stated, “We are very pleased to partner with Dr. Reddy’s in India. Dr. Reddy’s has had a very well established and respected presence in Russia for over 25 years and is one of the leading pharmaceutical companies in India. India is amongst most severely impacted countries from COVID 19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID 19. RDIF partners will receive an effective and safe drug to fight the coronavirus. The platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences.”
G V Prasad, Co-Chairman and Managing Director of Dr. Reddy’s Laboratories stated, “We are pleased to partner with RDIF to bring the vaccine to India. The Phase-I and II clinical trials have shown promising results. We will be conducting Phase-III trials in India to ensure safety and efficacy for the Indian population and to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India.”
On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and have become the world’s first registered vaccine towards COVID-19 based mostly on the human adenoviral vectors platform.
On September 4, a analysis paper on the outcomes of Phase I and Phase II medical trials of the Sputnik V vaccine was revealed in The Lancet, one of many main worldwide medical journals, demonstrating no severe opposed results and a secure immune response in 100% of members. Post-registration medical trials of the Sputnik V vaccine involving 40,000 volunteers are at present ongoing. More than 55,000 volunteers have utilized to participate in post-registration trials. The first outcomes of those trials are anticipated to be revealed in October-November 2020.